CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Date
2007Author
Economopoulos, T.Psyrri, A.
Dimopoulos, M. A.


Tsatalas, C.
Nikolaides, C.
Mellou, S.
Xiros, N.
Fountzilas, George
Source
Cancer JournalVolume
13Issue
5Pages
327-334Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas. In a secondary analysis we evaluated the impact of adding rituximab to CEOP-14/CEOP-21 chemotherapy. Study Design: The trial opened in March 1999, and patients were randomly assigned to either CEOP-14 or CEOP-21. All patients enrolled from May 2002 onward received rituximab with each chemotherapy cycle, and those attaining a complete response received rituximab consolidation. Results: Complete and overall response rates in the CEOP-21 ± rituximab (N ≤ 114) and CEOP-14 ± rituximab (N ≤ 103) arms were similar, as were the overall survival (P ≤ 0.769) and time to progression distributions (P ≤ 0.969). Rituximab was shown to have a beneficial effect both on the overall survival and on the time to progression. Conclusions: Thus far, no significant improvement in outcome has been demonstrated with CEOP-14 ± rituximab versus CEOP-21 ± rituximab. However, with addition of rituximab to CEOP-21/CEOP-14, significant improvements in time to progression and overall survival were achieved. © 2007 by Lippincott Williams & Wilkins.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group
Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...
-
Article
A phase-II study with idarubicin, etoposide and prednisone (IVPP), in patients with refractory or early relapsed intermediate or high grade non- Hodgkin's lymphoma [6]
Xiros, N.; Economopoulos, T.; Fountzilas, George; Pavlidis, Nicholas; Samantas, E.; Raptis, S. (1999)
-
Article
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP
Economopoulos, T.; Dimopoulos, M. A.; Mellou, S.; Pavlidis, Nicholas; Samantas, E.; Nikolaides, C.; Tsatalas, C.; Papadopoulos, A.; Papageorgiou, E.; Papasavvas, P.; Fountzilas, George (2002)Introduction: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has ...